REGENXBIO
Rockville
About REGENXBIO
REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $928.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (May 2025)
- Ticker: nasdaq:RGNX
- Website: regenxbio.com
- Phone: (202) 785-7438
Industries & Categories
Biopharma, Biotechnology, Genetics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/regenxbio-83197 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.